跳到正文
原文
Medical Xpress·· 8 天前AI 评分35

专家警告制药公司肥胖症去污名化宣传活动

Experts urge caution over drug company campaigns to destigmatize obesity

AI 导读

专家在《英国医学杂志》上警告,制药公司通过去污名化肥胖症的宣传活动可能会影响公共对话和政策方向,尽管这种做法在科学上合理且有益,但存在商业利益驱动的风险,可能导致对肥胖症根源问题的关注减弱。

正文
body mass index
Credit: Unsplash/CC0 Public Domain

We should be wary of campaigns by pharmaceutical companies to destigmatize obesity, say experts in The BMJ. Michael Viggars and colleagues argue that, while destigmatizing obesity is the right thing to do, there is a risk that companies profiting from obesity treatment come to influence public conversation and national policy.

They point to Eli Lilly's U.K. "Obesity Is a Disease" campaign, which explains that obesity is a complex disease rather than a failure of willpower, that the body can resist weight loss, and that people who have struggled for years deserve compassion, not blame.

Advertisements invite people to check their body mass index, answer a few questions and prepare for a conversation with a doctor, nurse or pharmacist. Although drugs are not mentioned, the campaign is by a pharmaceutical company whose drug tirzepatide is now a principal treatment for obesity.

Almost everything the campaign says about stigma is true, note the authors. The framing is at once scientifically defensible and commercially useful, and that convergence, they say, is exactly what makes it harder to criticize.

"This is what the commercial determinants of health look like in their subtlest form," they argue. "We spot commercial influence far less readily when it arrives wrapped in the language of compassion and destigmatization that public health has spent years cultivating."

The risk is not mainly that more people will be prescribed weight loss drugs; for eligible patients that is a clear benefit, they write. The risk is that it endorses a clinical-first approach to obesity that narrows the field of action.

If obesity is understood primarily as a disease awaiting clinical intervention, responsibility and resources may drift away from its upstream causes including poor urban planning, the food environment, deprivation and marketing, they explain. "Obesity treatment and prevention may be quietly recast as only a personal, medical matter rather than a collective responsibility."

Addressing this requires us to balance two perspectives: that destigmatizing obesity is the right thing to do and that we should be wary of the vested interest pharmaceutical companies have in tackling that stigma, they write.

"Regulators should be willing to test the principles and identify the limits of the code by reference to campaigns like this one by a manufacturer, not only in relation to the pharmacies, clinics or influencers selling or promoting the drugs," they conclude.

Publication details

We should be wary of campaigns by pharmaceutical companies to destigmatise obesity, The BMJ (2026). DOI: 10.1136/bmj-2026-101360

Journal information: British Medical Journal (BMJ)

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Experts urge caution over drug company campaigns to destigmatize obesity (2026, November 11) retrieved 11 November 2026 from https://medicalxpress.com/news/2026-11-experts-urge-caution-drug-company.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com